Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value is HK$8,988.26 Mil.
Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Alebund Pharmaceuticals (Jiangsu)'s EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value is HK$8,988.26 Mil.
Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Alebund Pharmaceuticals (Jiangsu)'s EV-to-EBITDA at this moment.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Alebund Pharmaceuticals (Jiangsu) Enterprise Value Related Terms
Alebund Pharmaceuticals (Jiangsu) Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Enterprise Value Chart
Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend
Dec24
Dec25
Enterprise Value
0.00
0.00
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
Enterprise Value
0.00
0.00
HKSE:09637 vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value falls into.
Alebund Pharmaceuticals (Jiangsu) Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$8,988.26 Mil mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Enterprise Value of HK$8,988.26 Mil as of Sep. 10, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value too high?
Alebund Pharmaceuticals (Jiangsu)'s current Enterprise Value is HK$8,988.26 Mil. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value of HK$8,988.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current Enterprise Value is HK$8,988.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Enterprise Value of HK$8,988.26 Mil. The current Enterprise Value is HK$8,988.26 Mil. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Enterprise Value is HK$8,988.26 Mil as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
